Pfizer Inc. (PFE) Announces European Medicines Agency Acceptance of Regulatory Submissions For Two Investigational Cancer Therapies  
8/17/2011 11:30:27 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that the European Medicines Agency (EMA) has accepted Pfizer’s regulatory submissions for review of two investigational compounds - crizotinib, an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor, for the treatment of patients with previously treated ALK-positive advanced non-small cell lung cancer (NSCLC); and bosutinib for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase.